Federal Register / Vol. 62, No. 247 / Wednesday, December 24, 1997 / Notices 67395

adjournment on February 12. These

applications, proposals, and the

discussions could reveal confidential

trade secrets or commercial property

such as patentable material and

personal information concerning

individuals associated with the

applications and proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

Ms. Claudia Goad, Committee

Management Officer, National Institute

of Allergy and Infectious Diseases, Solar

Building, Room 3C2, National Institute

of Health, Bethesda, Maryland 20892,

301–496–7601, will provide a summary

of the meeting and a roster of committee

members upon request. Individuals who

plan to attend and need special

assistance, such as sign language

interpretation or other reasonable

accommodations, should contact Ms.

Goad in advance of the meeting.

Dr. Kevin M. Callahan, Scientific

Review Administrator, Allergy,

Immunology and Transplantation

Research Committee, NIAID, NIH, Solar

Building, Room 4C20, Bethesda,

Maryland 20892, telephone 301–496–

8424, will provide substantive program

information.

(Catalog of Federal Domestic Assistance

Program Nos. 93.855, Immunology, Allergic

and Immunologic Diseases Research,

National Institutes of Health)

Dated: December 16, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–33494 Filed 12–23–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and

Infectious Diseases; Notice of

Meetings: National Advisory Allergy

and Infectious Diseases Council;

Acquired Immunodeficiency Syndrome

Subcommittee; Allergy and

Immunology Subcommittee;

Microbiology and Infectious Diseases

Subcommittee

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the

National Advisory Allergy and

Infectious Diseases Council, National

Institute of Allergy and Infectious

Diseases, and its subcommittees on

February 2–3, 1998. Meetings of the

Council, NAAIDC Allergy and

Immunology Subcommittee, NAAIDC

Microbiology and Infectious Diseases

Subcommittee and the NAAIDC

Acquired Immunodeficiency Syndrome

Subcommittee will be held at the

National Institutes of Health, Bethesda,

Maryland.

The meeting of the full Council will

be open to the public on February 2 in

Building 31C, Conference Room 6, from

1 p.m. to approximately 3:30 p.m. for

general discussion and program

presentations.

On February 3 the meetings of the

NAAIDC Allergy and Immunology

Subcommittee, NAAIDC Microbiology

and Infectious Diseases Subcommittee

will be open to the public from 8:30

a.m. until adjournment. The

subcommittees will meet in Building

31C, conference rooms 8 and 6

respectively.

In accordance with the provisions set

forth in secs. 552b(c)(4) and 552b(c)(6),

Title 5, U.S.C. and sec. 10(d) of Pub. L.

92–463, the meeting of the NAAIDC

Acquired Immunodeficiency Syndrome

Subcommittee, NAAIDC Allergy and

Immunology Subcommittee and the

NAAIDC Microbiology and Infectious

Diseases Subcommittee will be closed to

the public for approximately four hours

for review, evaluation, and discussion of

individual grant applications. It is

anticipated that this will occur from

8:30 a.m. until approximately 1 p.m. on

February 2, in conference rooms 7, 8

and 6 respectively. The meeting of the

full Council will be closed from 3:30

p.m. until recess on February 2 for the

review, discussion, and evaluation of

individual grant applications. These

applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material, and personal information

concerning individuals associated with

the applications, disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Ms. Claudia Goad, Committee

Management Officer, National Institute

of Allergy and Infectious Diseases, Solar

Building, Room 3C26, National

Institutes of Health, Bethesda, Maryland

20892, 301–496–7601, will provide a

summary of the meeting and a roster of

committee members upon request.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Ms. Goad in advance of the

meeting.

Dr. Lawrence Deyton, Acting Director,

Division of Extramural Activities,

NIAID, NIH, Solar Building, Room

3C20, 6003 Executive Boulevard,

Rockville, Maryland 20892, telephone

301–496–7291, will provide substantive

program information.

(Catalog of Federal Domestic Assistance

Program Nos. 93.855 Immunology, Allergic

and Immunologic Diseases Research, 93.856,

Microbiology and Infectious Diseases

Research, National Institutes of Health)

Dated: December 16, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–33495 Filed 12–23–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and

Other Communication Disorders;

Notice of Meeting of the National

Deafness and Other Communication

Disorders Advisory Council and Its

Planning Subcommittee

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the

National Deafness and Other

Communication Disorders Advisory

Council and its Planning Subcommittee

on January 21–22, 1998, at the National

Institutes of Health, 9000 Rockville

Pike, Bethesda, Maryland. The meeting

of the full Council will be held in

Conference Room 6, Building 31C, and

the meeting of the Subcommittee will be

in Conference Room 7, Building 31C.

The meeting of the Planning

Subcommittee will be open to the

public on January 21 from 2 p.m. until

3 p.m. for the discussion of policy

issues. The meeting of the full Council

will be open to the public on January 22

from 8:30 a.m. until 11:30 a.m. for a

report from the Institute Director and

discussion of extramural policies and

procedures at the National Institutes of

Health and the National Institute on

Deafness and Other Communication

Disorders. Attendance by the public will

be limited to space available.

In accordance with the provisions set

forth in Sections 552b(c)(4) and

552b(c)(6), Title 5, United States Code

and Section 10(d) of Pub. L. 92–463, the

meeting of the Planning Subcommittee

on January 21 will be closed to the

public from 3 p.m. to adjournment. The

meeting of the full Council will be

closed to the public on January 22 from

12:30 p.m. until adjournment. The

meetings will include the review,

discussion, and evaluation of individual

grant applications. The applications and

the discussions could reveal

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the

applications, the disclosure of which